Chicago Prostate Cancer Center First In World To Reach 100 Patient Implants Using Cesium-131(TM), Isotope From IsoRay Medical, Inc.

CHICAGO--(BUSINESS WIRE)--Chicago Prostate Cancer Center (CPCC) reached a major milestone in prostate brachytherapy (radioactive seed implantation) October 4, 2006, becoming the world’s first cancer center to treat 100 patients using Cesium-131™, a powerful new medical isotope developed and manufactured by IsoRay Medical, Inc.